

Award Number: W81XWH-16-1-0496

TITLE: Synthetic lethal therapeutic approaches for ARID1A-mutated ovarian cancer

PRINCIPAL INVESTIGATOR: Rugang Zhang, Ph.D.

CONTRACTING ORGANIZATION: The Wistar Institute of Anatomy & Biology
Philadelphia, PA 19104

REPORT DATE: October 2017

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2017		2. REPORT TYPE Annual		3. DATES COVERED 30Sep2016 - 29Sep2017	
4. TITLE AND SUBTITLE Synthetic lethal therapeutic approaches for ARID1A-mutated ovarian cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-16-1-0496	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Rugang Zhang E-Mail: rzhang@wistar.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Wistar Institute 3601 Spruce Street Philadelphia, PA 19104-4265				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies in the United States. Among all EOC subtypes, ovarian clear cell carcinoma (OCCC) carries the worst prognosis when diagnosed at an advanced stage, and there is currently no effective therapy for this disease. The gene <i>ARID1A</i> , which encodes a subunit of the epigenetic SWI/SNF chromatin-remodeling complex, is the highest mutated gene in OCCC that occurs in over 50% of the cases. In addition, <i>ARID1A</i> is also mutated in ~30% of endometrioid subtype of EOC. Since <i>ARID1A</i> is the highest mutated gene and a known driver mutation in OCCC, we performed an unbiased screen and demonstrated that in <i>ARID1A</i> -mutated OCCC the inhibition of EZH2, another epigenetic regulator, is synthetically lethal. In addition to EZH2, our unexplored data suggest that <i>ARID1A</i> -mutated ovarian cancer cells are also selectively sensitive to the inhibition of HDAC6. Our <u>central hypothesis</u> is that <i>ARID1A</i> -mutated ovarian cancers can be treated and ultimately eradicated based on the synthetic lethality through targeting EZH2 and HDAC6 using clinically applicable small molecule inhibitors. <u>The objective of this proposal</u> is to develop first effective targeted therapeutic approach for <i>ARID1A</i> -mutated ovarian cancers.					
15. SUBJECT TERMS Epithelial ovarian cancer, ovarian clear cell carcinoma, ARID1A, SWI/SNF, synthetic lethality					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 14	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments.....	4
4. Impact.....	11
5. Changes/Problems.....	11
6. Products.....	12
7. Participants & Other Collaborating Organizations.....	13
8. Special Reporting Requirements.....	14
9. Appendices.....	14

1. INTRODUCTION:

Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies in the United States. Among all EOC subtypes, ovarian clear cell carcinoma (OCCC) carries the worst prognosis when diagnosed at an advanced stage, and there is currently no effective therapy for this disease. The gene *ARID1A*, which encodes a subunit of the epigenetic SWI/SNF chromatin-remodeling complex, is the highest mutated gene in OCCC that occurs in over 50% of the cases. In addition, *ARID1A* is also mutated in ~30% of endometrioid subtype of EOC. Since *ARID1A* is the highest mutated gene and a known driver mutation in OCCC, we performed an unbiased screen and demonstrated that in *ARID1A*-mutated OCCC the inhibition of EZH2, another epigenetic regulator, is synthetically lethal. In addition to EZH2, our unexplored data suggest that *ARID1A*-mutated ovarian cancer cells are also selectively sensitive to the inhibition of HDAC6. Our central hypothesis is that *ARID1A*-mutated ovarian cancers can be treated and ultimately eradicated based on the synthetic lethality through targeting EZH2 and HDAC6 using clinically applicable small molecule inhibitors.

2. KEYWORDS:

Epithelial ovarian cancer, ovarian clear cell carcinoma, ARID1A, SWI/SNF, synthetic lethality.

3. ACCOMPLISHMENTS:

What were the major goals and objectives of the project?

The objective of this proposal is to develop the first effective targeted therapeutic approach for *ARID1A*-mutated ovarian cancers.

Specific Aim 1: To investigate the molecular basis underlying the observed synthetic lethality between *ARID1A* mutation and inhibition of HDAC6 activity.

Specific Aim 2: To investigate the effects of a combination therapeutic strategy for *ARID1A*-mutated ovarian cancer by simultaneously inhibiting HDAC6 and EZH2.

What was accomplished under these goals?

Since the starting of the award, substantial progress has been made toward achieving the goals as outlined in the application.

ARID1A-inactivated cells are selectively sensitive to HDAC6 inhibition.

To examine the role of specific HDACs in the context of *ARID1A*-mutated ovarian cancers, we performed an unbiased short hairpin RNA (shRNA) knockdown-based evaluation against eleven histone deacetylase genes. This was done in the context of *ARID1A* wildtype ovarian clear cell RMG1 cells with or without ARID1A knockdown (**Fig. 1a**).




Figure 1. ARID1A-inactivated cells are selectively sensitive to HDAC6 knockdown. (a-c) ARID1A and a loading control GAPDH protein expression in ARID1A wildtype RMG1 cells with or without ARID1A knockdown (a). Cells were transduced with lentivirus encoding shRNA to each of the 11 individual HDACs (HDAC1-11) and subjected to colony formation assay. Scatterplot of the integrated density normalized to control. The x-axis indicates changes in cell growth induced by individual shHDACs in control ARID1A wildtype treated cells, while the y-axis indicates changes in cell growth induced by the same shHDACs in shARID1A-expressing cells. Individual HDACs are indicated with their respective numbers (b). $n=4$ independent experiments. Colony formation by the indicated cells (c). (d-f) ARID1A protein expression in parental and ARID1A CRISPR OVCA429 cells (d). Colony formation assay using the indicated OVCA429 cells with or without HDAC6 knockdown (e), which was quantified (f). $n=3$ independent experiments. (g-h) A panel of cell lines with known ARID1A mutational status with or without HDAC6 knockdown were grown in 3D using Matrigel. Shown are acini formed by the indicated cells (g). Scale bar = 75 AU in NIH Image J software. The diameters of acini ($n=50$; representative of three biological repeats) were quantified (h). $n.s.$ indicates not significant. Error bars represent mean with S.E.M. P -value calculated via two-tailed t -test.

ARID1A knockdown allows us to mimic loss of ARID1A protein expression caused by >90% of *ARID1A* mutations in ovarian cancer³ and to ensure the same genetic background for the unbiased evaluation. We transiently transduced pooled shRNAs for each of the 11 individual HDACs in *ARID1A* wildtype RMG1 cells with or without ARID1A knockdown. To measure changes in cell viability, these cells were subjected to a colony formation assay. Similar to previous reports¹, we observed no significant difference between *ARID1A* wildtype RMG1 cells with or without ARID1A knockdown (**Fig. 1b-c**). HDAC6 knockdown showed the highest selectivity against ARID1A knockdown with the least growth inhibitory effects on controls (**Fig. 1b**). Likewise, HDAC6 knockdown was selective against ARID1A knockout in *ARID1A* wildtype OVCA429 cells (**Fig. 1d-f**).




Figure 2. The selectivity against ARID1A mutation depends on the enzymatic activity of HDAC6.

(a-b) Expression of HDAC6, FLAG and a loading control β -actin in *ARID1A*-mutated TOV21G cells expressing a shHDAC and concurrent expression of FLAG-tagged shRNA resistant wildtype HDAC6 or a catalytically inactive H216/611A mutant (a). The indicated cells were subjected to colony formation assay and integrated density was measured (b). $n=4$ independent experiments. (c) IC_{50} of HDAC6 inhibitor ACY1215 is significantly higher in *ARID1A* wildtype ($n=4$ cell lines) than mutated ($n=4$ cell lines) cells. (d) Expression of ARID1A and a loading control β -actin in the indicated primary cultures of human ovarian clear cell carcinomas determined by immunoblot. (e) HDAC6 inhibitor ACY1215 dose response curves of primary clear cell ovarian tumor cultures with (VOA4841) and without (XVOA295) ARID1A expression. $n=3$ independent experiments. (f) Control and ARID1A CRISPR OVCA429 cells were treated with or without 1.25 μ M ACY1215 in a colony formation assay. (g) Quantification of (f). $n=4$ independent experiments. (h-j) Immunoblots of the indicated proteins in *ARID1A*-mutated TOV21G cells with or without wildtype ARID1A restoration (h). The indicated cells treated with or without ACY1215 were plated in 24-well plates in quadruplicates and subjected to colony formation assay for 12 days, after which they were stained with 0.05% crystal violet (shown are cells treated with 625 nM ACY1215). Note that ARID1A restoration inhibits the growth of *ARID1A*-mutated cells^{1,2}. To limit the potential bias in colony formation, the number of cells used for ARID1A restored cells were 2-fold of the control *ARID1A*-mutated cells (i). Integrated density was measured with NIH Image J software as a surrogate for cell growth (j). The concentrations of ACY1215 were 312 nM and 625 nM, respectively. $n=4$ independent experiments. Error bars represent mean with S.E.M. P -value calculated via two-tailed t -test.

ARID1A status correlates with response to HDAC6 inhibition.

We next validated the initial findings in a panel of clear cell ovarian cancer cell lines in 3 dimensional (3D) cultures using Matrigel extracellular matrix that more closely mimics the tumor microenvironment. HDAC6 knockdown had no appreciable effect on the growth of *ARID1A* wildtype cells but significantly suppressed the growth of *ARID1A*-mutated cells (**Fig. 1g-h**). The observed growth inhibition depends on the enzymatic activity of HDAC6 because the growth inhibition was rescued by a wildtype HDAC6 but not a catalytically inactive H216/611A mutant ⁴ (**Fig. 2a-b**).

Notably, selective and specific HDAC6 inhibitors have been developed. We tested the HDAC6 inhibitor ACY1215 (Rocilinostat) ⁵ in a panel of cell lines with or without *ARID1A* mutation because it was safe in clinical trials ⁶. Compared with *ARID1A* wildtype cells, the IC₅₀ of ACY1215 was significantly lower in *ARID1A*-mutated cells (**Fig. 2c**). Primary clear cell ovarian tumor cultures without ARID1A expression are more sensitive to ACY1215 compared to those with ARID1A expression (**Fig. 2c-d**). The IC₅₀ values of ACY1215 in primary cells are comparable to those observed in cell lines (**Fig. 2c-e**). ARID1A knockout significantly increased the sensitivity of *ARID1A* wildtype OVCA429 cells to ACY1215 (**Fig. 2f-g**). Conversely, restoration of wildtype ARID1A in *ARID1A*-mutated TOV21G cells reduced the sensitivity of these cells to ACY1215 (**Fig. 2h-j**). We conclude that ARID1A-inactivated cells are selectively sensitive to HDAC6 inhibition.

HDAC6 inhibition triggers apoptosis in ARID1A-inactivated cells.

We next determined the mechanism whereby HDAC6 inhibition suppresses the growth of ARID1A-inactivated cells. HDAC6 inhibitor ACY1215 treatment induced apoptosis of *ARID1A*-inactivated cells as shown by an increase in Annexin V positive cells and upregulation of cleaved caspase 3 and cleaved PARP p85 (**Fig. 3a-c**). Consistent with the observed selectivity of HDAC6 inhibition in cells with ARID1A inactivation (**Fig. 1**), ACY1215 did not induce a significant increase in apoptosis in *ARID1A* wildtype cells (**Fig. 3b-e**), and wildtype ARID1A restoration suppressed ACY1215 induced apoptosis in *ARID1A*-mutated TOV21G cells (**Fig. 3f-g**). Compared with *ARID1A* wildtype controls, the HDAC6 inhibitor ACY1215 or knockdown of HDAC6 increased markers of apoptosis in ARID1A knockdown cells (**Fig. 3d-e**). Notably, a pan-caspase inhibitor Q-VD-Oph or knockdown of intrinsic apoptotic pathway initiator caspase 9 or effector caspase 3 ⁷ significantly suppressed the apoptosis induced by ACY1215 (**Fig. 3h-i**). We conclude that HDAC6 inhibition promotes apoptosis in ARID1A-inactivated cells.




Figure 3. HDAC6 inhibition induces apoptosis in ARID1A inactivated cells. (a) *ARID1A*-mutated TOV21G cells treated with 1.25 μ M ACY1215 or DMSO control were examined for expression of markers of apoptosis cleaved caspase 3, cleaved PARP p85 or a loading control GAPDH by immunoblot. (b) Percent apoptosis in the indicated cell lines was quantified by FACS based on Annexin V staining. (c) Percent apoptosis of in the indicated primary clear cell ovarian tumor cultures was quantified by FACS based on Annexin V staining. (d) *ARID1A* wildtype RMG1 cells with the indicated knockdown of ARID1A, HDAC6, or a combination was examined for expression of apoptotic markers cleaved caspase 3 and cleaved PARP p85 and a loading control GAPDH by immunoblot. (e) *ARID1A* wildtype RMG1 cells with or without ARID1A knockdown were treated with 1.25 μ M ACY1215. Expression of apoptotic markers cleaved caspase 3 and cleaved PARP p85 and a loading control GAPDH determined by immunoblot. (f) Expression of ARID1A and a loading control β -actin in TOV21G cells with or without wildtype ARID1A restoration. (g) Percent apoptosis based on Annexin V staining in *ARID1A*-mutated TOV21G cells with or without wildtype ARID1A restoration and treated with 1.25 μ M ACY1215 or DMSO controls for 96 hrs. (h) Percent apoptosis based on Annexin V staining in *ARID1A*-mutated TOV21G cells treated with 1.25 μ M ACY1215, 20 μ M pan-caspase inhibitor Q-VD-Oph or a combination for 48 hrs. (i) Percent apoptosis based on Annexin V staining in *ARID1A*-mutated TOV21G cells treated with 1.25 μ M ACY1215 for 48 hrs with or without knockdown of caspase 3 or caspase 9. For quantifications in b, c, g, h and i, n=3 independent experiments. Error bars represent mean with S.E.M. P-value calculated via two-tailed t-test.

REFERENCES

1. Bitler, B.G. *et al.* Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. *Nat Med* **21**, 231-238 (2015).
2. Guan, B., Wang, T.L. & Shih le, M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. *Cancer research* **71**, 6718-6727 (2011).
3. Wiegand, K.C. *et al.* ARID1A mutations in endometriosis-associated ovarian carcinomas. *N Engl J Med* **363**, 1532-1543 (2010).
4. Kawaguchi, Y. *et al.* The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. *Cell* **115**, 727-738 (2003).
5. Haggarty, S.J., Koeller, K.M., Wong, J.C., Grozinger, C.M. & Schreiber, S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. *Proc Natl Acad Sci U S A* **100**, 4389-4394 (2003).
6. Santo, L. *et al.* Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. *Blood* **119**, 2579-2589 (2012).
7. Strasser, A., O'Connor, L. & Dixit, V.M. Apoptosis signaling. *Annu Rev Biochem* **69**, 217-245 (2000).

What opportunities for training and professional development did the project provide?

“Nothing to Report.”

How were the results disseminated to communities of interest?

“Nothing to Report.”

What do you plan to do during the next reporting period to accomplish the goals and objectives?

In the next reporting period, we plan to:

- 1) Investigate the molecular mechanism underlying the observed selectivity against ARID1A inactivation by HDAC6 inhibition.
- 2) Investigate the effects of HDAC6 inhibition on the growth of ARID1A-inactivated OCCCs in vivo in preclinical models.

4. IMPACT:

“Nothing to Report.”

What was the impact on the development of the principal discipline(s) of the project?

“Nothing to Report.”

What was the impact on other disciplines?

“Nothing to Report.”

What was the impact on technology transfer?

“Nothing to Report.”

What was the impact on society beyond science and technology?

“Nothing to Report.”

5. CHANGES/PROBLEMS:

“Nothing to Report.”

Changes in approach and reasons for change

“Nothing to Report.”

Actual or anticipated problems or delays and actions or plans to resolve them

“Nothing to Report.”

Changes that had a significant impact on expenditures

“Nothing to Report.”

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

“Nothing to Report.”

6. PRODUCTS:

1. Wu S, Fatkhutdinov N, **Zhang R**. Harnessing mutual exclusivity between *TP53* and *ARID1A* mutations. **Cell Cycle**, in press.
2. Bitler BG, Wu S, Park PH, Hai Y, Aird KM, Wu S, Wang Y, Kossenkov AV, Rauscher FJ, Conejo-Garcia JR, Zou W, Speicher D, Huntsman DG, Cho KR, Christianson DW, **Zhang R**. *ARID1A*-mutated ovarian cancers depend on HDAC6 activity. **Nature Cell Biology**, 19: 962-973, 2017. PMCID: PMC5117661.
3. Goldman AR, Bitler BG, Schug Z, Conejo-Garcia JR, **Zhang R**, Speicher DW. The primary effect on the proteome of ARID1A-mutated ovarian clear cell carcinoma is downregulation of the mevalonate pathway at the post-transcriptional level. **Mol Cell Proteomics**, 15: 3348-3360, 2017. PMCID: PMC5098034.
4. Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu S, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, **Zhang R**. BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. **Cancer Research**, 76: 6320-6330, 2017. PMCID: PMC5117661.
5. Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Bradner JE, Conejo-Garcia JR, **Zhang R**. Epigenetic targeting of immuncheckpoint PD-L1 by BET bromodomain inhibition. **Cell Reports**, 16: 2829-37, 2016. PMCID: PMC5177024.
6. Wu S, **Zhang R**, Bitler BG. Arid1a controls tissue regeneration. **Stem Cell Investig**, 3:35, 2016. PMCID: PMC4981703.

Books or other non-periodical, one-time publications.

“Nothing to Report.”

Other publications, conference papers, and presentations.

“Nothing to Report.”

- **Website(s) or other Internet site(s)**

“Nothing to Report.”

- **Technologies or techniques**

“Nothing to Report.”

- **Inventions, patent applications, and/or licenses**

“Nothing to Report.”

- **Other Products**

“Nothing to Report.”

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS:

What individuals have worked on the project?

Name:	<i>Rugang Zhang</i>
Project Role:	<i>Principal Investigator</i>
Researcher Identifier (e.g. ORCID ID):	<i>N/A</i>
Nearest person month worked:	<i>1</i>
Contribution to Project:	Supervised the study.
Funding Support:	This award

Name:	<i>Takeshi Fukumoto</i>
Project Role:	<i>Postdoctoral Fellow</i>
Researcher Identifier (e.g. ORCID ID):	<i>N/A</i>
Nearest person month worked:	<i>11</i>
Contribution to Project:	Performed the study.
Funding Support:	This award

Name:	<i>Pingyu Liu</i>
Project Role:	<i>Postdoctoral Fellow</i>
Researcher Identifier (e.g. ORCID ID):	<i>N/A</i>
Nearest person month	<i>1</i>

worked:	
Contribution to Project:	Performed the study.
Funding Support:	This award

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

“Nothing to Report.”

What other organizations were involved as partners?

“Nothing to Report.”

8. SPECIAL REPORTING REQUIREMENTS: None

9. APPENDICES: None